Business
Niagen Bioscience, Inc. Reports First Quarter 2025 Financial Results and Increases Outlook
Total net sales of $30.5 million, up $8.3 million or 38% year-over-year, gross margin of 63.4%, net income of $5.1 million and Adjusted EBITDA of $4.9
About this update from Niagen Bioscience, Inc.
[{"type":"text","content":"\nTotal net sales of $30.5 million, up $8.3 million or 38% year-over-year, gross margin of 63.4%, net income of $5.1 million and Adjusted EBITDA of $4.9 million for the three months ended March 31, 2025 and increased full year 2025 outlook.\n\n LOS ANGELES--(BUSINESS WIRE)--\nNiagen Bioscience, Inc. (NASDAQ:NAGE) today announced financial results for the first quarter of 2025.\n\nFirst Quarter 2025 Financial and Recent Operational Highlights\n\n\nTotal net sales were $30.5 million, with $21.5 million from Tru Niagen®, up 38%, and 24%, respectively, from the prior year quarter.\n\n\nTotal Niagen® ingredient sales, including food-grade and pharmaceutical-grade, reached $8.0 million, up 95% YoY.\n\n\nDelivered strong gross margin of 63.4%, up 270 basis points from the prior year quarter.\n\n\nSales and marketing expense as a percentage of net sales was 26.6%, an improvement of 380 basis points, compared to 30.4% from the prior year quarter.\n\n\nDelivered net income of $5.1 million or $0.07 earnings per share, an improvement of $5.6 million and $0.08 per share from the prior year quarter.\n\n\nAdjusted EBITDA, a non-GAAP measure, was $4.9 million, a $4.2 million improvement from the prior year quarter.\n\n\nTotal cash provided by operations of $7.9 million, ending the quarter with $55.6 million in cash.\n\n\nIncreased full year 2025 outlook: Net sales growth expected between 20%–25% (previously approximately 18%), reflecting continued strength in the expanding NAD+ market. Adjusted general and administrative expenses now expected to increase $7.0–$8.0 million (previously $5.0–$6.0 million), primarily due to revised share-based compensation estimates. Full year 2025 outlook continues to project profitability.\n\n\nThe Company announced its corporate name change to Niagen Bioscience, Inc. and commenced trading under the new Nasdaq ticker “NAGE,” effective March 19, 2025. This rebrand reflects the Company’s legacy and leadership in healthy aging through its flagship ingredient, Niagen®, reinforcing its renewed mission: “There’s a better way to age.”\n\n\nOn March 20, 2025, the Company expanded its NAD+ precursor intellectual property portfolio with a newly granted patent which covers the composition of matter for nicotinamide riboside (NR) salt forms, including NR Malate and NR Tartrate, and other NR derivatives. This is part of a fam...